

# Canada

Population 2016

36 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.099 (0.098–0.1)	0.27 (0.27–0.27)
Mortality (HIV+TB only)	0.023 (0.015–0.033)	0.06 (0.04–0.09)
Incidence (includes HIV+TB)	1.9 (1.6–2.2)	5.2 (4.4–6)
Incidence (HIV+TB only)	0.15 (0.12–0.18)	0.41 (0.34–0.49)
Incidence (MDR/RR-TB)**	0.019 (<0.01–0.031)	0.05 (0.02–0.09)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.067 (0.057–0.077)	0.81 (0.69–0.94)	0.88 (0.75–1)
Males	0.076 (0.064–0.087)	0.92 (0.79–1.1)	1 (0.85–1.1)
Total	0.14 (0.12–0.16)	1.7 (1.5–2)	1.9 (1.6–2.2)

TB case notifications, 2016	
Total cases notified	1 738
Total new and relapse	1 738
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	44%
- % pulmonary	72%
- % bacteriologically confirmed among pulmonary	91%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	92% (80–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.07 (0.06–0.08)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	97	13%
- on antiretroviral therapy		

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			15 (6–23)
Estimated % of TB cases with MDR/RR-TB	0.82% (0.33–1.7)	6.3% (1.7–15)	
% notified tested for rifampicin resistance	79%	80%	1 403
MDR/RR-TB cases tested for resistance to second-line drugs			16
Laboratory-confirmed cases		MDR/RR-TB: 16, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 16, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	84%	1 642
Previously treated cases, excluding relapse, registered in 2015		
HIV-positive TB cases registered in 2015	84%	67
MDR/RR-TB cases started on second-line treatment in 2014	87%	23
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB